Alnylam Pharmaceuticals
NEWS
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.
The U.S. Food and Drug Administration gave Akcea Therapeutics and its parent company Ionis Pharmaceuticals the green light for Tegsedi, its treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
After negative reports about after-hours parties that have been deemed disrespectful toward women, and multiple reports about the lack of gender diversity on industry boards of directors, biotech’s biggest trade association is taking action.
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Alnylam Pharmaceuticals, Inc. (ALNY) securities between February 15, 2018 through September 12, 2018 (the “Class Period”).
Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) in presently in the midst of a Phase 3 study of givosiran, reporting that the drug has been successful in a clinical trial. The company hopes to use their trial data in getting givosiran approved by the U.S. Food and Drug Administration (FDA).
Here’s a look at who’s making moves in the biotech and pharma world this week.
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
One year after stepping down from her role as president and chief operating officer of Celgene, Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals.
JOBS
IN THE PRESS